A normal hemostatic response to vascular injury requires both factor VIII (FVIII) and von
Willebrand factor (VWF). In plasma, VWF and FVIII normally circulate as a noncovalent …

The development of anti-drug antibodies (ADAs) following administration of biotherapeutics
to patients is a vexing problem that is attracting increasing attention from pharmaceutical …

Expansion of human regulatory T cells (Tregs) for clinical applications offers great promise
for the treatment of undesirable immune responses in autoimmunity, transplantation, allergy …

At first sight the bleeding disorder hemophilia A seems to have little in common with immune
disorders, but immunology research intersects with other disciplines including hematology …

Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

See also Miao CH. Tilt balance towards regulation: evolving new strategy for treatment of
hemophilia inhibitors. This issue, pp 1521–3. DOI: 10.1111/j. 1538‐7836.2011. 04351. x …

Activation of T-helper cells is dependent upon the appropriate presentation of antigen-
derived peptides on MHC class II molecules expressed on antigen presenting cells. In the …

Today it is generally accepted that B cells require cognate interactions with CD4+ T cells to
develop high-affinity antibodies against proteins. CD4+ T cells recognize peptides …

Background Several studies have suggested Black and Hispanic hemophilia A (HA) patients
in the United States suffer higher incidences of neutralizing anti-FVIII antibodies (inhibitors) …

In hemophilia A, the most severe complication of factor VIII (FVIII) replacement therapy
involves the formation of FVIII neutralizing antibodies, also known as inhibitors, in 25% to …